

**Table SI. Patients characteristics at initial diagnosis and response to treatment with topical carmustine (BCNU)**

Pat. No.	Age at diagnosis, years/Sex	Stage	Prior treatments	Concomitant therapy with BCNU	Time from diagnosis to BCNU initiation (months)	Clinical response	Time to response (months)	BCNU treatment duration to date (months)	Reason discontinued (if applicable)
1	56/Male	IB	NBUVB, TSEB, imiquimod	IFN $\alpha$	36	PR	7	11	
2	64/Male	IIB	Romidepsin	IFN $\gamma$ and isotretinoin	12	PR	2	5	
3	55/Male	IB	None	None	2	PR	4	7	
4	60/Male	IB	IFN $\alpha$ , targretin	UVB	144	PR	3	24	
5	32/Male	IB	PUVA, nitrogen mustard	None	24	PR	6	56	Enrolled in clinical trial
6	69/Male	IIIA		IFN $\alpha$	6	CR	3	42	
7	48/Male	IB	IFN $\alpha$ , Targretin, PUVA	IFN $\gamma$	22	PR	2	12	Irritation
8	72/Male	IIIB	PUVA, TSEB	IFN $\alpha$	24	CR	4	41	
9	41/Male	IA	None	None	0	PR	3	3	Hypersensitivity
10	63/Male	IB	IFN $\alpha$ and topical nitrogen mustard	IFN $\gamma$	12	CR	5	15	
11	58/Female	IB	PUVA, IFN $\alpha$ , Isotretinoin	None	120	CR	8	9	
12	80/Male	IIB	None	IFN $\alpha$	0	PR	7	10	Temporarily discontinued for elective unrelated orthopedic surgery
13	63/Male	IB	Nitrogen mustard	IFN $\gamma$	60	CR	4	19	

NBUVB: narrow-band ultraviolet B; TSEB: total skin electric beam therapy; INF: interferon; PUVA: psoralen and ultraviolet A.